14 April 2010
South Africa’s Adcock Ingram has announced the acquisition of a stake of just over 65% in Ghanaian pharmaceutical company Ayrton Drug Manufacturing for an undisclosed sum, giving the local firm a foothold in the West African region.
As part of the acquisition, Adcock CEO Jonathan Louw said the company had appointed three South Africans to the Ayrton board, providing an opportunity to “direct strategy for further expansion in the region and provide further support to the operational team.”
In a statement this week, Adcock added that Sam Adjepong, whose family founded the Ayrton Drug Manufacturing Company, would continue as the managing director of the business.
“Adjepong has a wealth of experience and knowledge of the Ghanaian pharmaceutical market and will help us to position Adcock Ingram’s business interests in Ghana and rest of the West African region,” Louw said.
“Adcock Ingram will launch an exciting portfolio of its products into West Africa. Ayrton has huge potential and mirrors much of the nature of the product range we have in South Africa, with a local plant focusing on manufacturing liquid and tablet formulations.
“This is a perfect strategic fit for both businesses,” Louw said.
Would you like to use this article in your publication or on your website? See: Using SAinfo material